Latest Oxaliplatin Stories

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix(®) (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive...

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. Harper, M.D., executive vice president...

In a retrospective study recently online by The Oncologist, Jason Faris, M.D., Medical Oncologist at the Massachusetts General Hospital Cancer Center in Boston, and colleagues described their institutional experience with the FOLFIRINOX treatment protocol in patients with locally advanced pancreatic cancer. Durham, NC (PRWEB) May 08, 2013 Treatment with neoadjuvant 5-FU, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) followed by chemoradiation shows substantial activity in patients...

Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix(®) (panitumumab) versus Erbitux(®) (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival. The...

TOKYO, Feb. 27, 2013 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI) ) to the Japanese Ministry of Health, Labor and Welfare. Taiho Pharmaceutical is seeking approval of TAS-102 for the indication of unresectable, advanced, recurrent...

PARIS and TARRYTOWN, N.Y., Feb. 5, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has granted marketing authorization in the European Union for ZALTRAP 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after...

CALGARY, Jan. 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced a poster presentation covering positive preliminary results from a Phase I study examining the intravenous administration of REOLYSIN in combination with FOLFIRI in patients with metastatic colorectal cancer (REO 022). The results were presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, which took place from January 24-26, 2013. The...

REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of the Oncotype DX(®) Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score(®) (RS) results changed treatment recommendations in 45 percent of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis...

PARIS and TARRYTOWN, N.Y., Nov. 16, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended the granting of marketing authorization for ZALTRAP(®) (ziv-aflibercept) Injection for Intravenous Infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI)...

CALGARY, Aug. 16, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.S. Phase I clinical trial using REOLYSIN in combination with FOLFIRI (Folinic Acid (leucovorin) with Fluorouracil (5-FU) and Irinotecan) in patients with oxaliplatin refractory, Kras mutant colorectal cancer (REO 022). The trial is a 21-patient, single arm dose escalation study designed to determine a maximum...